THE COST-EFFECTIVENESS OF ABATACEPT IN COMBINATION WITH METHOTREXATE FOR THE TREATMENT OF PATIENT WITH ACTIVE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN THE UNITED KINGDOM

被引：0
|
作者：
Lebmeier, M. [1 ]
Pericleous, L. [1 ]
Drost, P. [2 ]
Dequen, P. [3 ]
Ouwens, M. [4 ]
Bergman, G.
Baig, H. [1 ]
机构：
[1] Bristol Myers Squibb Pharmaceut Co, Uxbridge, Middx, England
[2] Bristol Myers Squibb, Braine Ialleud, Belgium
[3] Mapi Values, Bollington, Cheshire, England
[4] Mapi Values, Houten, Netherlands
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)72190-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [31] The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy
    Zachariae, Claus
    Mork, Nils-Jorgen
    Reunala, Timo
    Lorentzen, Henrik
    Falk, Edvard
    Karvonen, Seija-Liisa
    Johannesson, Anders
    Clareus, Birgitta
    Skov, Lone
    Mork, Gro
    Walker, Sian
    Qvitzau, Susanne
    ACTA DERMATO-VENEREOLOGICA, 2008, 88 (05) : 495 - 501
  • [32] Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
    Dipen Patel
    Ahmed Shelbaya
    Raymond Cheung
    Jyoti Aggarwal
    Sang Hee Park
    Javier Coindreau
    Advances in Therapy, 2019, 36 : 2086 - 2095
  • [33] Safety and Efficacy of Abatacept Over 4 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in the AIM Trial
    Russell, A. S.
    Kremer, J. M.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2608 - 2609
  • [34] Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment
    Russell, A. S.
    Wallenstein, G. V.
    Li, T.
    Martin, M. C.
    Maclean, R.
    Blaisdell, B.
    Gajria, K.
    Cole, J. C.
    Becker, J-C
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) : 189 - 194
  • [35] Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Muszbek, Noemi
    Proudfoot, Clare
    Fournier, Marie
    Chen, Chieh-I
    Kuznik, Andreas
    Kiss, Zsofia
    Gal, Peter
    Michaud, Kaleb
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1268 - 1280
  • [36] Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis
    Patel, Dipen
    Shelbaya, Ahmed
    Cheung, Raymond
    Aggarwal, Jyoti
    Park, Sang Hee
    Coindreau, Javier
    ADVANCES IN THERAPY, 2019, 36 (08) : 2086 - 2095
  • [37] Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study
    Genovese, Mark C.
    Fleischmann, Roy
    Kivitz, Alan J.
    Rell-Bakalarska, Maria
    Martincova, Renata
    Fiore, Stefano
    Rohane, Patricia
    van Hoogstraten, Hubert
    Garg, Anju
    Fan, Chunpeng
    van Adelsberg, Janet
    Weinstein, Steven P.
    Graham, Neil M. H.
    Stahl, Neil
    Yancopoulos, George D.
    Huizinga, Tom W. J.
    van der Heijde, Desiree
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) : 1424 - 1437
  • [38] Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate.
    Dougados, M
    Westhovens, R
    St Clair, EW
    Aranda, R
    Nuamah, I
    Zhou, Y
    Vratsanos, G
    Becker, JC
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S185 - S185
  • [39] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis in korea
    Sung, YK
    Choi, CB
    Park, EJ
    Kim, JJ
    Park, SJ
    Lee, EK
    Bae, SC
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S236 - S236
  • [40] A cost-effectiveness analysis of treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis.
    Choi, HK
    Seeger, JD
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S389 - S389
12345